Treatment of Contact Dermatitis from Poison Ivy

Immediate Management

The American Heart Association recommends washing the exposed area with soap and water or a commercial decontamination product as soon as possible after exposure, which can remove up to 100% of poison ivy oils (urushiol) if done immediately, but effectiveness decreases to 50% at 10 minutes and 10% at 30 minutes 1, 2
Even washing 2 hours after exposure can reduce symptoms by 55-70% 1
Various cleaning products (commercial decontamination products, hand cleaners, dishwashing soap) show similar effectiveness 1, 2

Apply cool compresses to the affected area to relieve local symptoms, as recommended by the American College of Cardiology 1, 2
Oatmeal baths may provide relief for itching and inflammation, according to the American Heart Association 1, 2

Over-the-counter topical steroids: Evidence for effectiveness is uncertain - low-potency corticosteroids (0.2-2.5% hydrocortisone) have not shown significant symptom improvement in studies, with a low strength of evidence 1, 3
Over-the-counter antihistamines: Evidence for effectiveness in reducing itching is uncertain, though they may help with sleep at night, with a low strength of evidence 1, 2
High-potency prescription topical corticosteroids combined with systemic corticosteroids have been shown to reduce the duration of itching, with a moderate strength of evidence 1

Contact dermatitis from poison ivy is self-limiting, typically lasting 2-3 weeks, according to the American Heart Association 1
The extent and severity of symptoms are proportional to the area and duration of exposure, with a high strength of evidence 1
Approximately 50-75% of individuals react to urushiol, the allergic compound in poison ivy, with a moderate strength of evidence 1

In all patients, discouraging scratching reduces the risk of secondary bacterial infection, manifested by warmth, tenderness, purulent drainage, or honey‑colored crusting. 4

For mild to moderate dermatitis (≤30 % body‑surface area), high‑potency prescription topical corticosteroids (e.g., clobetasol 0.05 % or fluocinonide 0.05 % cream/ointment) provide superior symptom control compared with low‑potency agents. 5
In moderate cases (10–30 % BSA), the same high‑potency topical corticosteroids are recommended as the primary pharmacologic intervention. 5

In severe dermatitis (>30 % BSA or with significant facial/genital involvement), oral prednisone is the standard systemic agent and should be combined with high‑potency topical steroids to shorten the duration of itching; evidence is of moderate strength. 5
Hospitalized patients with extensive involvement may require intravenous methylprednisolone to achieve rapid control of inflammation. 5

The same anti‑scratching measures and topical corticosteroid recommendations used for adults apply to pediatric patients, helping to prevent secondary infection. 4

Topical corticosteroids are generally considered safe for use during pregnancy, allowing effective local control without known fetal harm. 6
Systemic corticosteroids should be reserved for pregnant patients only when the therapeutic benefit outweighs potential risks, following standard risk‑benefit assessment. 6

Greasy or occlusive topical products should be avoided because they impede wound exudate absorption and increase the likelihood of superinfection. 4